Creating a new RNA treatment for ovarian cancer
Official title: Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer
Funded at Nuago Therapeutics INC · NIH-11065199 · Data updated 2026-11-12
This study is testing a new RNA-based treatment for ovarian cancer that helps kill cancer cells while being gentle on healthy tissues, aiming to improve your quality of life and potentially cure or manage the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nuago Therapeutics INC NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | June 9, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $400,000 |
| NIH project number | 1R42CA291346-01A1 |
| Project ID | NIH-11065199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with ovarian cancer who have not responded well to existing treatments.
✕Less likely to help
Patients with non-cancerous conditions or those with cancers that are not ovarian may not benefit from this research.
What this research studies
This research focuses on developing a novel RNA-based therapy aimed at treating ovarian cancer by inducing a specific type of cell death that cancer cells cannot resist. The approach utilizes short interfering RNAs (sRNAs) that target multiple survival genes in cancer cells, effectively silencing them and preventing the cancer from growing. The therapy is designed to be safe for normal tissues, minimizing side effects and improving the quality of life for patients. The goal is to provide a treatment that can either cure the cancer or manage it as a chronic condition.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment for ovarian cancer that is effective and has fewer side effects than current therapies.
How similar studies have gone: This approach is based on innovative research that has shown promise in targeting cancer cells effectively, suggesting potential for success in this novel application.
Where this research is happening
-
Nuago Therapeutics INC
Chicago, United States Active
Researchers
- Principal investigator: Schickel, Robert — Nuago Therapeutics INC
- Study coordinator: Schickel, Robert
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.